ASCO2018

Preliminary data from the first clinical trial of the company’s intracranial ultrasound implant, SonoCloud®, show a good safety profile and promising trends in overall survival.

Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) presented a preliminary analysis of the data from 21 glioblastoma patients who received 65 SonoCloud® treatments. Overall Survival was increased from 8.5 to 12.9 months in patients who had SonoCloud®-induced BBB opening.